Intellia (NTLA), CRISPR Therapeutics (CRSP) Receive U.S. Patent for CRISPR/Cas9 Ribonucleoprotein Complexes – StreetInsider.com
Markets Daily |
Intellia (NTLA), CRISPR Therapeutics (CRSP) Receive U.S. Patent for CRISPR/Cas9 Ribonucleoprotein Complexes
StreetInsider.com Intellia Therapeutics, Inc. (NASDAQ: NTLA) and CRISPR Therapeutics AG (NASDAQ: CRSP), two leading genome editing companies focused on the development of potentially curative therapies, announced that the United States Patent and Trademarks … Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein … Variation on CRISPR technology advances potential cures | The … Crispr Therapeutics AG (CRSP) Insider Samarth Kulkarni Sells 11615 Shares |
